Ang II administration is a well-recognized model of cardiovascular and renal disease (44–46), and the therapeutic benefits of RAS inhibition are almost certainly in large part a consequence of reduced Ang II stimulation of the AT1 receptor in high renin, high Ang II conditions such as renal artery stenosis and heart failure. The gene discussed is AGT; the disease is kidney disorder.